USPTO serial 98921336
LCB
Reviewed by CopyMark Law Group
Status 730Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- OJEYEMI, ASHLEY CHRISTINE
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with LCB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $150
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Yuseong-gu, Daejeon, KR
Yuseong-gu, Daejeon, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Richard Y. Kim
Richard Y. Kim Snell & Wilmer L.L.P.One East Washington Street, Suite 2700Phoenix, AZ 85004-2556United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Vaccines; food supplements; vitamin preparations; crude drugs, namely, natural remedy preparations for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; nutraceuticals for use as a dietary supplement; biological preparations for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical pharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical molecular diagnostic reagents for medical use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; biopharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; pharmaceutical preparations, namely, medical pharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; cough syrups for pharmaceutical purposes; lozenges for pharmaceutical purposes; cachets for pharmaceutical purposes; chemico-pharmaceutical preparations; antibodies for medical purposes and medical laboratory tests; drugs for medical purposes, namely, medical pharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical preparations, namely, antibodies for medical purposes, antibody conjugates and active ingredients and antibody conjugates; chemical reagents for medical use, namely, chemical reagents for linking molecules for medical use; pharmaceutical compositions; extracts of medicinal plants, other than essential oils, for pharmaceutical purposes; pharmaceuticals; medicines for human purposes; pharmaceutical products; antibiotics; anti-cancer preparations; mixed vitamin preparations; chemotherapeutics; pharmaceutical preparations for treatment of rare diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 24, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 23, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 23, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 23, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 3, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 9, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 9, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 3, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 12, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 23, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 23, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 23, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 9, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 9, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 9, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 3, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 24, 2024 | NWAP | NEW APPLICATION ENTERED | — |